product name Geniposidic acid
Description: Geniposidic acid is an iridoid glucoside, used to treat inflammation, jaundice and hepatic disorders. Geniposidic acid shows a more remarkable inhibitory activity factor against implanted tumor growth when the doses of 500 mg/kg are given alone or combined with irradiation. Geniposidic acid improves the plaque area, intima/media thickness ratio, and intimal foam cells number in rabbits. Geniposidic acid (100 μg/mL) results in relieving ECs shedding and improving aortic morphology disorders in rabbits. Geniposidic acid (100 μg/mL) performs significant inhibition on smooth muscle cells proliferation in rabbits. Geniposidic acid results in obvious inhibition on SMC migration from the upper chamber.
References: Cancer Lett. 1997 Feb 26;113(1-2):31-7; Pharm Biol. 2015 Feb;53(2):280-5; J Ethnopharmacol. 2013 Mar 7;146(1):271-7.
374.34
Formula
C16H22O10
CAS No.
27741-01-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 16 mg/mL (42.7 mM)
Water: <1 mg/mL
Ethanol: 2 mg/mL (5.3 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Geniposidic acid shows a more remarkable inhibitory activity factor against implanted tumor growth when the doses of 500 mg/kg are given alone or combined with irradiation. Geniposidic acid improves the plaque area, intima/media thickness ratio, and intimal foam cells number in rabbits. Geniposidic acid (100 μg/mL) results in relieving ECs shedding and improving aortic morphology disorders in rabbits. Geniposidic acid (100 μg/mL) performs significant inhibition on smooth muscle cells proliferation in rabbits. Geniposidic acid results in obvious inhibition on SMC migration from the upper chamber. Geniposidic acid increases survival rate of rats with fulminant hepatic failure. Geniposidic acid attenuates the following effects: GalN/LPS increases serum aminotransferase activity, serum tumor necrosis factor-α level and hepatic lipid peroxidation and decreases hepatic glutathione content. Geniposidic acid augmentes increases in serum interleukin-6 level, heme oxygenase-1 and NF-E2-related factor 2 protein expression in rats with fulminant hepatic failure. Geniposidic acid decreases cleaved caspase-8 and caspase-3 protein expression and shows significantly fewer apoptotic cells in rats with fulminant hepatic failure. Geniposidic acid increases Bcl-xL protein expression and decreased Bax protein expression in rats with fulminant hepatic failure. Geniposidic acid treatment enhances phosphorylation of signal transducer and activator of transcription 3 in rats with fulminant hepatic failure. |
| Animal model | |
| Formulation & Dosage | |
| References | Cancer Lett. 1997 Feb 26;113(1-2):31-7; Pharm Biol. 2015 Feb;53(2):280-5; J Ethnopharmacol. 2013 Mar 7;146(1):271-7. |
